deutetrabenazine deutetrabenazine deutetrabenazine (trade name austedo) is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with huntington's disease and tardive dyskinesia. deutetrabenazineclinical datatrade namesaustedoother namestetrabenazine d6; sd809; sd-809ahfs/drugs.commonographmedlineplusa617022license data us dailymed: deutetrabenazine pregnancycategory au: b3 routes ofadministrationby mouthatc coden07xx16 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only identifiers iupac name (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzoquinolizin-2-one cas number1392826-25-3pubchem cid73437646drugbankdb12161chemspider34222717uniip341g6w9nbkeggd10701chemical and physical dataformulac19h21d6no3molar mass323.462 g·mol−1 chemically, deutetrabenazine is an isotopic isomer of tetrabenazine in which six hydrogen atoms have been replaced by deuterium atoms. the incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing. efficacy a lancet study published on 28 june 2017 carried out a review between 29 october 2014 and 19 august 2016 where 298 patients were randomly assigned to receive at least one of the following: one dose of placebo per day, one dose of deutetrabenazine 12 mg/day, one dose of deutetrabenazine 24 mg/day, or one dose of deutetrabenazine 36 mg/day. from baseline to week 12, the least-squares mean aims (abnormal involuntary movement scale) score improved by −3.3 points in the deutetrabenazine 36 mg/day group, −3.2 points in the 24 mg/day group, −2.1 points in the 12 mg/day group, and −1.4 points in the placebo group. deutetrabenazine 24 mg/day and 36 mg/day provided a significant reduction in tardive dyskinesia, with favourable safety and tolerability. these findings suggest that dosing regimens could be individualized and tailored for patients on the basis of dyskinesia control and tolerability. pharmacology pharmacodynamics deutetrabenazine acts as a monoamine-depleting agent. history teva pharmaceuticals received approval from the food and drug administration to market deutetrabenazine in early 2017, along with five years of orphan drug exclusivity for the treatment of chorea associated with huntington's disease. it was the first deuterated drug to receive fda approval.